SCHEMBL9688064

SCHEMBL9688064

Cc1cc(-c2ccc(=O)[nH]n2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
PDE4A P27815 3/20 0.55
PDE4B Q07343 3/20 0.55
PDE4C Q08493 3/20 0.55
PDE4D Q08499 3/20 0.55
PDE3B Q13370 6/20 0.52
PDE3A Q14432 6/20 0.52
CYP1A2 P05177 2/20 0.50
PIM1 P11309 2/20 0.48
CDC7 O00311 1/20 0.48
CSNK2A2 P19784 1/20 0.48
CLK1 P49759 1/20 0.48
GSK3B P49841 1/20 0.48
CSNK2B P67870 1/20 0.48
CSNK2A1 P68400 1/20 0.48
CSNK2A3 Q8NEV1 1/20 0.48
TP53 P04637 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12595727 0.85 LMNA (0.66) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL11140405 0.85 LMNA (0.56) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL7304379 0.82 LMNA (0.62) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL9687256 0.81 LMNA (0.51) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595734 0.81 LMNA (0.60) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL11740736 0.81 LMNA (0.60) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL5765567 0.80 PDE4A (0.76) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12596010 0.80 LMNA (0.55) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595743 0.78 PDE4A (0.78) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595819 0.78 LMNA (0.57) LMNAMEN1KMT2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501731-B2 Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-08-06 US disclosed
US-20110112061-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2011-05-12 US disclosed
US-5135932-A 2-HYDROXYPROPYLAMINO-ALKYL-BENZIMIDAZOLY-5-YL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART DISEASE DR. KARL THOMAE GMBH (DE) 1992-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112061-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF PDXK, PNPO, HCCS LMNA 109/4885MEN1 424/4885KMT2A 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.